Federal Register
Notice: FDA has determined the regulatory review period for Asta Medica’s Cetrotide is 2,103 days for extending a patent that claims that human drug product. Cetrotide is indicated for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation. To view this notice, click here.